State Key Laboratory of Medical Proteomics, National Center for Protein Sciences-Beijing, Beijing Proteome Research Center, Beijing Institute of Lifeomics, Beijing, 102206, China.
School of Basic Medical Sciences, Anhui Medical University, Hefei, Anhui 230032, China.
J Am Soc Mass Spectrom. 2024 Jun 5;35(6):1310-1319. doi: 10.1021/jasms.4c00083. Epub 2024 May 23.
The accumulation of amyloid beta (Aβ1-42) results in neurotoxicity and is strongly related to neurodegenerative disorders, especially Alzheimer's disease (AD), but the underlying molecular mechanism is still poorly understood. Therefore, there is an urgent need for researchers to discover the proteins that interact with Aβ1-42 to determine the molecular basis. Previously, we developed peptide-ligand-induced changes in the abundance of proTeinS (PACTS)-assisted thermal proteome profiling (TPP) to identify proteins that interact with peptide ligands. In the present study, we applied this technique to analyze clinical samples to identify Aβ1-42-interacting proteins. We detected 115 proteins that interact with Aβ1-42 in human frontal lobe tissue. Pathway enrichment analysis revealed that the differentially expressed proteins were involved mainly in neurodegenerative diseases. Further orthogonal validation revealed that Aβ1-42 interacted with the AD-associated protein mitogen-activated protein kinase 3 (MAPK3), and knockdown of the Aβ1-42 amyloid precursor protein (APP) inhibited the MAPK signaling pathway, suggesting potential functional roles for Aβ1-42 in interacting with MAPK3. Overall, this study demonstrated the application of the PACTS-TPP in clinical samples and provided a valuable data source for research on neurodegenerative diseases.
淀粉样蛋白 β(Aβ1-42)的积累会导致神经毒性,并与神经退行性疾病密切相关,尤其是阿尔茨海默病(AD),但其潜在的分子机制仍知之甚少。因此,研究人员迫切需要发现与 Aβ1-42 相互作用的蛋白质,以确定其分子基础。以前,我们开发了肽配体诱导的蛋白丰度变化(PACTS)辅助热蛋白组分析(TPP)来鉴定与肽配体相互作用的蛋白质。在本研究中,我们应用该技术分析临床样本,以鉴定与 Aβ1-42 相互作用的蛋白质。我们在人额叶组织中检测到 115 种与 Aβ1-42 相互作用的蛋白质。通路富集分析显示,差异表达的蛋白质主要参与神经退行性疾病。进一步的正交验证表明,Aβ1-42 与 AD 相关蛋白丝裂原活化蛋白激酶 3(MAPK3)相互作用,而 Aβ1-42 淀粉样前体蛋白(APP)的敲低抑制了 MAPK 信号通路,表明 Aβ1-42 与 MAPK3 相互作用具有潜在的功能作用。总之,本研究证明了 PACTS-TPP 在临床样本中的应用,并为神经退行性疾病的研究提供了有价值的数据源。